George E. Anastassov, MD, CEO of AXIM Biotech, told us the main rationale behind using chewing gum as the delivery system for Cannabidiol (CBD) is that “the oral-pharyngeal mucosa offers​ extensive territory for rapid and controlled absorption of the API and the avoidance of first pass metabolism​.” “Within 20 minutes, the oral mucosa absorbs 80 […]

by

Taking a selfie seems like a harmless act, but it caused serious negative health effects for one teenager. Doctors at Dalhousie University in Canada discovered a young girl, who previously suffered from a seizure, experienced seizure-like episodes moments after she took a selfie, according to a case study.  Read: Cannabidiol, A Compound In Marijuana, May Reduce […]

by

Posted in: Medical Research News | Medical Condition News | Pharmaceutical News Tags: Ache, Acute Pain, Antidepressant, Calcium, Calcium Channel Blocker, Cannabis, Cluster Headache, Headache, Migraine, Musculoskeletal, Neurology, Pain, Pharmaceutical, Prophylaxis, Stomach, Stomach Pain … read more at: https://www.news-medical.net/news/20170624/Cannabinoids-found-to-be-suitable-treatment-for-migraine-attacks.aspx

by

OAKPOINTE COMMUNITIES AND PRESIDIO RESIDENTIAL CAPITAL RECEIVE CITY APPROVAL TO DEVELOP LAKEPOINTE URBAN VILLAGE, A 214-ACRE MASTERPLANNED COMMUNITY   Mixed-Use Development in Southeastern King County to Include 850,000-Square-Foot Entertainment and Lifestyle Center, More Than 1,500 Homes, a 20-Acre Lake, Open Space and Trails   Oakpointe Communities and Presidio Residential Capital have received unanimous approval from the […]

by

NEW YORK, Nov. 21, 2017 (GLOBE NEWSWIRE) — AXIM® Biotechnologies, Inc. (AXIM® Biotech) (OTC:AXIM), a world leader in cannabinoid research and development, today announced clinical trial results from its first phase II pilot trial for the treatment of irritable bowel syndrome (IBS) with the company’s CanChew +® CBD (cannabidiol) functional, controlled release chewing gum. The […]

by

­­ NEW YORK, Nov. 22, 2017 (GLOBE NEWSWIRE) — AXIM® Biotechnologies, Inc. (AXIM® Biotech) (OTC:AXIM), a world leader in cannabinoid research and development, today announced results for the quarter ended September 30, 2017, and provided an overview of recent operational highlights. “We are very excited to see clinical evidence of our theory and the therapeutic […]

by

Over 20 abstracts released online today from Phase 3 programs in Lennox-Gastaut Syndrome and Dravet syndrome and from Expanded Access Program LONDON, Nov. 21, 2017 (GLOBE NEWSWIRE) — GW Pharmaceuticals plc (Nasdaq:GWPH) (“GW,” “the Company” or “the Group”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, […]

by

NEW YORK, Nov. 21, 2017 (GLOBE NEWSWIRE) — AXIM® Biotechnologies, Inc. (AXIM® Biotech) (OTC:AXIM), a world leader in cannabinoid research and development, today announced clinical trial results from its first phase II pilot trial for the treatment of irritable bowel syndrome (IBS) with the company’s CanChew +® CBD (cannabidiol) functional, controlled release chewing gum. The […]

by

NEW YORK, Nov. 21, 2017 (GLOBE NEWSWIRE) — AXIM® Biotechnologies, Inc. (AXIM® Biotech) (OTC:AXIM), a world leader in cannabinoid research and development, today announced clinical trial results from its first phase II pilot trial for the treatment of irritable bowel syndrome (IBS) with the company’s CanChew +® CBD (cannabidiol) functional, controlled release chewing gum. The […]

by

Over 20 abstracts released online today from Phase 3 programs in Lennox-Gastaut Syndrome and Dravet syndrome and from Expanded Access Program LONDON, Nov. 21, 2017 (GLOBE NEWSWIRE) — GW Pharmaceuticals plc (Nasdaq:GWPH) (“GW,” “the Company” or “the Group”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, […]

by

Results of a Phase 1 clinical trial in healthy volunteers show that PTL101, an oral cannabidiol compound, is a safe and effectively delivered potential treatment of spasticity in multiple sclerosis (MS) and for conditions like epilepsy, Harvest One Cannabis announced. These findings were published in the journal Clinical Pharmacology in Drug Development, in the study “Single-Dose Pharmacokinetics of Oral Cannabidiol Following Administration of […]

by

According to a report by Forbes, Brightfield Group, a cannabis market research firm indicates that the international market for cannabis is projected to hit $31.4 billion by 2021. Bethany Gomez, Director of Research for Brightfield Group, explained that the U.S. market is so much larger than the rest of the international markets combined. Currently, the […]

by